Drug Trial Radar · NCT07807865
A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Feb 18, 2030
Study completion Mar 4, 2030
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess how safe ITI-1284 is and how well it can be tolerated in long-term, when given alone or with other medicines, in participants with generalized anxiety disorder (GAD) who have not responded to treatment previously. GAD is a mental health condition defined by constant, uncontrollable worry about everyday things that lasts for six months or more.
Conditions
- Generalized Anxiety Disorder
Interventions
ITI-1284Drug
ITI-1284 will be administered sublingually.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to Week 52
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CalNeuro Research
Los Angeles, California · Recruiting
Sunshine Medical Research Studies Inc
Miami, Florida · Recruiting
SPRI Clinical Trials, LLC
Brooklyn, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.